Metabolic Phenotypes in Melanoma
Recruiting · NCT05570227 · Interventional (participants receive a specific treatment) · Lead sponsor: Peter MacCallum Cancer Centre, Australia
View the official record on ClinicalTrials.gov →Interventions studied
[U-13C]Glucose Infusion
What this trial is about
This is a single centre, correlative, longitudinal, biomarker study that aims to describe the metabolic features of human melanoma using mass spectrometry.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patient has provided written informed consent
- Male or female aged 18 years or older at written informed consent
- Presence of a known melanoma lesion requiring surgical excision or biopsy
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing biopsies and receiving a stable isotope infusion (where applicable)
Exclusion criteria
- Patients who meet any of the following criteria will be excluded from receiving a \[U-13C\]Glucose infusion:
- Diabetes mellitus
- Pregnancy or breast feeding
- Patients unable to comply with study procedures and follow up in the opinion of the investigator
Where it is running
1 location listed.
- Peter Mac Callum Cancer Centre - Melbourne, Victoria, Australia